Treatment-resistant schizophrenia: How far have we traveled?
Treatment-resistant schizophrenia is a lack of adequate response to antipsychotic medications resulting in incomplete functional and social recovery from the illness. Different definitions have been proposed for clinical practice and research work. Antipsychotics that are used in the management of s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.994425/full |
| _version_ | 1811282609671503872 |
|---|---|
| author | Ambu Pandey Kamal Narayan Kalita |
| author_facet | Ambu Pandey Kamal Narayan Kalita |
| author_sort | Ambu Pandey |
| collection | DOAJ |
| description | Treatment-resistant schizophrenia is a lack of adequate response to antipsychotic medications resulting in incomplete functional and social recovery from the illness. Different definitions have been proposed for clinical practice and research work. Antipsychotics that are used in the management of schizophrenia mainly act on multiple dopaminergic pathways which are implicated in the development of symptoms of schizophrenia. Newer antipsychotics also are implicated to affect the serotonergic pathways. Clozapine is the only evidence-based treatment available for the management of treatment-resistant cases. Neurobiologically, there is a considerable overlap between treatment-resistant and treatment-responsive cases. The factors that are implicated in the evolution of treatment resistance are still not conclusive. These make the management of such patients a challenge. However, certain peculiarities of treatment-resistant schizophrenia have been identified which can guide us in the early identification and precise treatment of the treatment-resistant cases. |
| first_indexed | 2024-04-13T01:55:40Z |
| format | Article |
| id | doaj.art-0769b6efebc7412aa4855c44f50078a4 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-13T01:55:40Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-0769b6efebc7412aa4855c44f50078a42022-12-22T03:07:46ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-08-011310.3389/fpsyt.2022.994425994425Treatment-resistant schizophrenia: How far have we traveled?Ambu Pandey0Kamal Narayan Kalita1Department of Psychiatry, Maharshi Devraha Baba Autonomous State Medical College, Deoria, IndiaDepartment of Psychiatry, Lokpriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, IndiaTreatment-resistant schizophrenia is a lack of adequate response to antipsychotic medications resulting in incomplete functional and social recovery from the illness. Different definitions have been proposed for clinical practice and research work. Antipsychotics that are used in the management of schizophrenia mainly act on multiple dopaminergic pathways which are implicated in the development of symptoms of schizophrenia. Newer antipsychotics also are implicated to affect the serotonergic pathways. Clozapine is the only evidence-based treatment available for the management of treatment-resistant cases. Neurobiologically, there is a considerable overlap between treatment-resistant and treatment-responsive cases. The factors that are implicated in the evolution of treatment resistance are still not conclusive. These make the management of such patients a challenge. However, certain peculiarities of treatment-resistant schizophrenia have been identified which can guide us in the early identification and precise treatment of the treatment-resistant cases.https://www.frontiersin.org/articles/10.3389/fpsyt.2022.994425/fulltreatment-resistanttreatment-refractoryneurobiologyclozapinepharmacogenomicsprecision-medicine |
| spellingShingle | Ambu Pandey Kamal Narayan Kalita Treatment-resistant schizophrenia: How far have we traveled? Frontiers in Psychiatry treatment-resistant treatment-refractory neurobiology clozapine pharmacogenomics precision-medicine |
| title | Treatment-resistant schizophrenia: How far have we traveled? |
| title_full | Treatment-resistant schizophrenia: How far have we traveled? |
| title_fullStr | Treatment-resistant schizophrenia: How far have we traveled? |
| title_full_unstemmed | Treatment-resistant schizophrenia: How far have we traveled? |
| title_short | Treatment-resistant schizophrenia: How far have we traveled? |
| title_sort | treatment resistant schizophrenia how far have we traveled |
| topic | treatment-resistant treatment-refractory neurobiology clozapine pharmacogenomics precision-medicine |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.994425/full |
| work_keys_str_mv | AT ambupandey treatmentresistantschizophreniahowfarhavewetraveled AT kamalnarayankalita treatmentresistantschizophreniahowfarhavewetraveled |